Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adapalene + tazarotene is a topical combination of two synthetic retinoids, both derivatives of vitamin A, used primarily in dermatology. Adapalene and tazarotene act as agonists at retinoic acid receptors (RARs) in the skin, modulating gene expression to regulate cell proliferation, differentiation, and inflammation. Both agents are indicated for the treatment of acne vulgaris; tazarotene is also approved for psoriasis and photoaging symptoms such as facial wrinkling and discoloration. Tazarotene is considered more potent but may cause more irritation than adapalene. The combination leverages their complementary mechanisms to enhance efficacy in treating acne by unclogging pores, reducing inflammation, normalizing keratinocyte differentiation, and suppressing inflammatory pathways[1][3][4][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adapalene + tazarotene.